Introduction
Marijuana is a commonly used substance during pregnancy in the United States. Seven percent of pregnant women self-report using marijuana during the prior 2-12 months, and among pregnant women who use marijuana, 16% report near-daily use. 1 There have been mixed findings with respect to whether perinatal marijuana use is causally associated with adverse obstetric or neonatal outcomes. [2] [3] [4] [5] A growing body of evidence, however, suggests that risks outweigh benefits of perinatal marijuana use. 6 The American Academy of Pediatrics has concluded that perinatal marijuana exposure has negative effects on short-term infant neurobehavior and longer-term behavior and cognition in childhood. 7 In July 2015, the American College of Obstetricians and Gynecologists issued a committee opinion concluding that marijuana use in pregnancy may be associated with impaired fetal neurodevelopment and that pregnant women be screened for and, where relevant, treated for, marijuana use. 8 Additionally, there may be important behavioral pathways through which infants or young children have increased health risks because of parents' marijuana use. 9 As of October 2016, 26 states permitted marijuana for medical use, and of those states, 5 also permitted marijuana for recreational use (including the District of Columbia). An additional 8 states approved medical or recreational use in voter referenda in the fall 2016 election; notably, California approved recreational marijuana use. Concurrently with state policy changes, public opinion about the risk-benefit ratio of marijuana use is also changing, with recent public opinion data indicating that 58% of the US public supports legalization of marijuana use. 10 Public health agencies may play a role in communicating information to the public about perinatal marijuana use. A large literature has documented the impact of communications content and presentation on the public's knowledge and attitudes. [11] [12] [13] [14] [15] To our knowledge, no research has examined communications from public health agencies pertaining to perinatal marijuana use. Our objective was to analyze the volume and content of published health communication about perinatal marijuana use by state and federal public health agencies.
Methods
The theoretical framework for this study is the mental models framework, which posits that risk communications can iteratively address the gaps between the public's mental model and the experts' mental model of a given issue. 16 The mental models approach has proven especially valuable in areas that are fraught with scientific uncertainty 17 or value judgments, [18] [19] [20] as is the case with perinatal marijuana use, because the approach can flexibly incorporate subjective determinants of health behavior decisions. The mental models approach to risk communication aims to ensure that the public can understand not only the basic information about a health risk but how well science understands the risk and its magnitude. . We used the search function on each agency's Web site to search for the terms (marijuana or cannabis or hemp) and (pregnancy or pregnant or prenatal or perinatal). If the agency's search function did not produce any results, we additionally conducted a Google search with the aforementioned search terms in addition to the name of the public health agency to ensure that we identified all relevant content. We saved all Web content as a PDF file to be used for coding, and so that we are able to access the item in the future, as Web links are not stable over time. 21 (A comprehensive list of all Web pages that we accessed, the corresponding dates the searches were conducted, and a PDF file of any content, as of the date accessed, is available from the authors upon request.)
Coding instrument development
We use directed content analysis methods to identify and code content about the risks or benefits of perinatal marijuana use, which allowed us to create categories of content related to our a priori outcomes of interest, as well as to address related categories of content that occur in the data. 22 We developed a 12-item coding instrument that included codes related to content about target populations (nonpregnant adult, pregnant women/fetus/infant, partner to pregnant woman, male reproductive, or childhood); mode of consumption (combustible inhalation, edible, transdermal, or noncombustible inhalation); or perinatal health (legal implications, quitting, or safety/parenting). These content domains included in our coding instrument were developed based on prior qualitative research with pregnant women who used marijuana and obstetric providers. Specifically, our prior qualitative work with pregnant women revealed that they often used Web searching as a tool to obtain information about marijuana's effects on fetal and infant health and that they felt that health care providers were not providing adequate information about marijuana use. 23 Prior work with obstetric providers showed that they were not aware of identified risks of perinatal marijuana use. 24 We created a coding scheme that included codes for a priori outcomes. We pilot-tested the coding instrument in a random sample of 14 Web pages about perinatal marijuana use that were not from US public health agencies (i.e., content from English language non-US public health agencies or content from consumer medical Web sites). Two authors (M.J., J.Z.) separately coded the first 5 pilot media items, met to compare codes, discussed inconsistency in coding approaches, and then altered or added codes for content not related to predetermined outcomes. They repeated this process for the remaining items to develop the coding instrument (Table A1 shows the full coding instrument).
After pilot testing of the instrument was complete, 2 authors (M.J., J.Z.) then independently coded all content about perinatal marijuana use published by state and federal US public health agencies. We used prevalence-and bias-adjusted kappa statistics, which provide a measure of interrate reliability that is adjusted to assess reliability for binary items where "yes" and "no" values are not evenly distributed. 25 Interrater reliability was moderate to excellent, with prevalence-and bias-adjusted k ranging from 0.58 to 1.00 and mean k D 0.87. (Table A2 shows raw agreement, Cohen's k, and prevalence-and biasadjusted k for each specific item.) Where there was disagreement in coding for specific items, the 2 coders discussed and reached agreement for the final analytic dataset.
Analysis
We conducted descriptive statistics to assess the characteristics of public health agency Web sites with perinatal marijuana content and to determine the frequency with which specific quantitative items were mentioned. For information related to perinatal use, we also grouped text into themes about health effects, legal implications, quitting marijuana use, and safety/ parenting and present illustrative quotes for these themes.
Results
Ten state public health agencies and 1 federal agency (National Institute on Drug Abuse [NIDA]) had published content pertaining to perinatal marijuana use. Among the state agencies with published information about perinatal marijuana, 5 states did not permit marijuana use, 4 states permitted marijuana for medical and recreational use, and 1 state permitted marijuana for medical use only. Most public health agency content (8 agencies) was targeted to the lay public, although 3 agencies had published content about perinatal marijuana use targeted to health care providers. The mean word count of published content was 1149 (SD: 168). Figure 1 show the frequency with which public health agency Web sites' content pertaining to perinatal marijuana included information on specific topics. Among the 11 agencies with perinatal marijuana use content, 2 mentioned marijuana use among women's partners, 2 mentioned marijuana use and male reproductive health, and 3 mentioned in utero exposure to marijuana among children aged 1-9. Most agencies mentioned combustible inhalation of marijuana (n D 10) or edible marijuana (n D 8). Eight of 11 agencies mentioned marijuana use and breastfeeding, 5 mentioned quitting marijuana in the perinatal period, 5 mentioned safety or parenting and marijuana use, and 3 mentioned legal implications of perinatal use.
Content for lay public audiences
Content published by public health agencies typically highlighted effects on infants and children, although the specific health effects mentioned varied across states (Table 1) . Among published content about perinatal health effects targeted to the lay public, information ranged from blanket Health effects among women, Public audience: fetuses, or infants "Some studies have suggested that among women who smoke marijuana cigarettes regularly, there is an increased chance for pregnancy complications such as: premature birth, low birth weight, stillbirth and small length and small head circumference. Babies that are born prematurely or with low birth weight can have higher rates of infant deaths, learning problems or other disabilities. Similar to what is seen with cigarette smoking, smoking marijuana may increase carbon monoxide levels in the blood, which can decrease the amount of oxygen the baby receives, and may also affect the growth of the baby." Health care provider audience: "Use of marijuana during pregnancy is associated with negative effects on exposed children, no matter when it is used during pregnancy. The negative effects include decreased academic ability, cognitive function and attention. These effects may not appear until adolescence." Health effects during breastfeeding Public audience: "Marijuana can be passed to infants through their mother's breast milk. Marijuana may also affect the quality and quantity of breast milk that you make." Health care provider audience: "Discuss importance of cessation of marijuana and other potentially harmful substances during pregnancy and breastfeeding and offer support if needed … Discuss patient's plan for marijuana use after pregnancy. statements (e.g., "There is no known safe amount of marijuana use during pregnancy") to lists of adverse effects (e.g., "there is an increased chance for pregnancy complications such as: premature birth, low birth weight, stillbirth and small length and small head circumference"). Three agencies explicitly described scientific uncertainty about the causal effects of perinatal marijuana use, and 1 state mentioned the difficulty in drawing inference from observational data: "It can be difficult to draw conclusions from these studies because most of the women who used marijuana also used other substances at the same time or had other factors that may have increased their chance for these defects." All 8 agencies mentioning breastfeeding stated that marijuana can be passed to infants via breast milk. Some agencies (n D 3) mentioned that infants exposed to marijuana might have trouble feeding. Five public health agency Web sites mentioned that pregnant women should stop using marijuana. These agencies universally directed women to talk to a doctor or other health care provider. Colorado, where marijuana has been legal for medical and recreational purposes since January 2014, also included a toll-free telephone number that pregnant or breastfeeding women could call for help to stop using marijuana.
Content for health care providers
Three states had information targeted to health care providers. Notably, these states (Alaska, Colorado, Washington) all have laws permitting recreational use of marijuana among adults. These documents generally discussed health effects of marijuana use in the perinatal period; for example, one state agency noted that "emerging research … suggests there is an association between marijuana and decreased fetal growth, development and executive functioning and mood disorders in children." Content targeted to health care providers also included information about states' policies pertaining to the circumstances under which health care providers are required to report prenatal substance use to child protective agencies. Two state agencies noted that mandatory reporting is required if health care providers "have a suspicion of abuse or neglect (i.e., that the health or welfare of a child is threatened)." The third state agency noted that reporting to a child protective agency is required for "newborns identified as being AFFECTED by illegal substance abuse or withdrawal symptoms resulting from prenatal drug exposure."
Discussion
In our study of all state public health agency Web sites and 5 federal health agency Web sites, we found that 11 contained published content about perinatal marijuana use. All state agencies included information about health effects related to in utero exposure to marijuana, and most (n D 8) also stated that marijuana can be passively consumed by an infant during breastfeeding. Content pertaining to health effects of perinatal marijuana use varied across state agencies, with public health messages ranging from broad statements about risk to more narrow messages about specific health effects. Fewer agencies had published messages about behaviorally based health risks to infants that occur with safety/parenting and marijuana use. Although public health agencies' content generally conveyed that perinatal marijuana use is associated with adverse effects, less than half of the content included resources to help individuals stop using marijuana in the perinatal period.
In light of emerging scientific evidence about the health risks to women, infants, and children from perinatal marijuana use, public health agencies face a challenging decision about whether or how to communicate potentially conflicting data to the lay public or health care providers. That we found only 10 state public health agencies had published such communications might reflect this challenge. In general, those states with published content often included information about health risks of perinatal marijuana use, but less frequently addressed the issue of scientific uncertainty in public communications. Public health agencies also face a challenge in disseminating credible information to the public about potential risks of perinatal marijuana use in an era when youth and younger adults increasingly believe marijuana use to be low risk or beneficial. 26 Nevertheless, there are at least 2 important reasons why public health agencies should consider disseminating information about perinatal marijuana use. First, current public opinion is likely to be heavily shaped by political and commercial messages about marijuana-for example, the public is already being exposed to marketing communications intended to promote marijuana use for recreational purposes. 27 This suggests a role for public health agencies to monitor and communicate unbiased findings. Second, women who have used marijuana during pregnancy report that they desire information about the risks of perinatal marijuana use and report actively seeking such information on the Internet or from family and friends. 23 Such research suggests that pregnant women would be receptive to information about how marijuana use might affect the health and well-being of infants and children.
In the 3 states where recreational marijuana is legal, public health agencies have published content about perinatal marijuana use for health care providers. Content aimed at providers included scientific information about health risks and treatment for dependent patients. Dissemination of such information to providers may be useful because of women's and infants' frequent engagement with the health care system during the perinatal period. Recent research suggests that obstetric providers describe limited knowledge about potential consequences of perinatal marijuana use, 24 and their responses to pregnant patients' disclosure of use of marijuana use often focus more on punitive consequences than medical implications. 28 Public health communications targeted to providers may serve a valuable role in summarizing emerging evidence pertaining to both health effects of perinatal marijuana use as well as best practices for screening and treatment.
This study has limitations. First, our analysis included state and federal public health agencies in the United States, so findings are likely not generalizable to other media about perinatal marijuana use, such as blogs or news Web sites. Second, our data were collected during one point in time (early 2016), so we are not able to assess changes over time in the public health messages about perinatal marijuana use. Given that policies legalizing marijuana for recreational use are relatively recent, however, we would expect that our data reasonably represent public health messages since the enactment of such policies. Third, our study is descriptive in nature, and we are unable to identify what proportion of pregnant or postpartum women are exposed to the public health messages about perinatal marijuana use or whether such messages lead to behavior changes. A strength of our study is that our content analysis methods involved the development of a codebook to identify common elements in text publications, and we used well-established methods to develop codes and provide quantitative estimate of high interrater reliability.
Conclusion
This systematic content analysis of public health agency Web sites in the United States found that of 56 state and federal agencies, 1 federal agency and 10 state agencies had published information about perinatal marijuana use. Public health messages commonly focused on potential adverse health effects, although the detail in such information varied across states. Fewer than half of agency Web sites provided resources to stop using marijuana in the perinatal period.
Funding
This research was supported by the Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program (K12 HD043441). The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors declare they have no conflicts of interest.
Author contributions
Dr. Jarlenski conceptualized the study design, contributed to data collection, analyzed the data, and approved the final version of the manuscript. Dr. Zank contributed to data collection, critically revised the manuscript for intellectual content, and approved the final version of the manuscript. Ms. Tarr and Dr. Chang contributed to the study design and interpretation of data, critically revised the manuscript for intellectual content, and approved the final version of the manuscript. Prevalence-and bias-adjusted kappa values account for some items that have very high or very low prevalence.
